CalciMedica (CALC) to Announce Earnings on Tuesday

CalciMedica (NASDAQ:CALC) is projected to issue its results before the market opens on Tuesday, August 11th. Analysts expect CalciMedica to announce earnings of ($0.33) per share for the quarter.

CalciMedica Trading Up 7.9%

NASDAQ CALC traded up $0.06 during trading hours on Tuesday, reaching $0.81. The company had a trading volume of 84,315 shares, compared to its average volume of 1,103,677. The stock has a 50-day moving average of $0.83 and a 200 day moving average of $1.04. The stock has a market capitalization of $12.83 million, a P/E ratio of -0.62 and a beta of 0.91. CalciMedica has a 1-year low of $0.46 and a 1-year high of $7.20.

Insider Activity at CalciMedica

In other CalciMedica news, Director Fred A. Middleton bought 248,972 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $199,177.60. Following the completion of the purchase, the director owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 28.25% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Institutional investors have recently bought and sold shares of the company. Cetera Investment Advisers raised its holdings in CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of CalciMedica in the fourth quarter valued at $127,000. Envestnet Asset Management Inc. raised its position in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after acquiring an additional 34,386 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in CalciMedica in the 4th quarter valued at approximately $506,000. Finally, Renaissance Technologies LLC boosted its stake in shares of CalciMedica by 26.1% during the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after acquiring an additional 18,300 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CalciMedica presently has an average rating of “Hold” and a consensus price target of $10.00.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.